-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 29, CDE's official website showed that Dongsun Pharmaceuticals, a class 3 generic drug called "Oseltamico co-suspension agent phosphate", was listed as the third domestic company to report the dosage form.
Oseltamivir is a specific inhibitor that acts on neuraminidase and inhibits the degeneration of mature influenza viruses from host cells, thereby inhibiting the spread of influenza viruses in the human body to act as a treatment for influenza.
oseltamivir's original research manufacturer is Roche, the product is called Duffy, in 2001 Oseltamivir capsules were approved in China;
in 2005 and 2006, Roche licensed Oseltamivir to Shanghai Sino-Western 3D Pharmaceuticals and Dongsun Pharmaceuticals for production, with the commodity names "Orfie" and "Kwi" listed for sale respectively.
and the production of three-dimensional pharmaceutical industry in China and the West oseltamivir as a government procurement drug, is not in circulation in the market, so the current domestic Oseltamivir market East Sunshine a large.
East Sunshine Pharmaceuticals' 2019 financial results show that total sales of Kwiat particles and cove capsules reached 5.93 billion yuan, accounting for 95.33 percent of the company's total turnover.
, the granule is the exclusive dosage form of Dongsun medicine, was approved for listing in 2008, the current market granule form only East Sunshine drug one obtained the production approval, patent protection period until 2026.
sales of Kwiat particles in 2019 were well higher than the 4.27 billion yuan in capsules and 1.66 billion yuan for capsules.
Insight database, Cinda Pharma (a subsidiary of Berry Pharmaceuticals) filed a listing application for Class 4 generics of Oseltamiel Capsules as early as December 2019 and is currently under review.
March 21, 2020, Xintai Pharmaceuticals oselavir dry suspension agent reported to the market, for the dosage form of the first domestic;
prior to Cinda Pharmaceuticals, already had Alvogen, Hetero's imported oseltamigo coin in domestic reports and is currently under review.
at present, oseltamivir capsules in addition to the shanghai West-West three-dimensional, Dongsun, Roche has been approved for listing, has Xintai Pharmaceutical, Chengdu Bent, Stone Pharmaceutical Group 4 newspapers listed;
however, in terms of raw materials, the current domestic only Yichang Dong Sunshine Changjiang Pharmaceutical, Shanghai China and the West three-dimensional to get the production approval, but the three-dimensional Chinese and Western have expired, only the East Sunshine's code in use;
from the supply of raw materials, The East Sunshine medicine still has its own advantages.
picture source: Insight database () Currently, Oseltamivir this heavy-selling variety of nearly 6 billion yuan is about to usher in a strong rival, but The East Sunshine's exclusive granulated type is still the best-selling and no competition, but dry mixer selling agent after being approved for the market may be its biggest threat;
.